Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Guided Therapeutics Inc
(OP:
GTHP
)
0.1799
UNCHANGED
Streaming Delayed Price
Updated: 3:57 PM EDT, Oct 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Guided Therapeutics Inc
Guided Therapeutics’ Announces Data from Chinese NMPA Clinical Study Signed Off by All Four Clinical Sites With Better Than Expected Results
July 10, 2024
From
Guided Therapeutics, Inc.
Via
Business Wire
Leading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results
February 20, 2024
From
Guided Therapeutics, Inc.
Via
Business Wire
Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval
November 20, 2023
From
Guided Therapeutics, Inc.
Via
Business Wire
Guided Therapeutics Provides Update on Start of Clinical Trial for US FDA Approval
May 01, 2023
From
Guided Therapeutics, Inc.
Via
Business Wire
Guided Therapeutics Announces New Agreement and Purchase Orders from Shandong Yaohua Medical Instrument Corporation
March 15, 2023
From
Guided Therapeutics, Inc.
Via
Business Wire
Guided Therapeutics Signs Agreement to Begin Clinical Trial for US FDA Approval
December 21, 2022
From
Guided Therapeutics, Inc.
Via
Business Wire
Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical Scan
November 09, 2022
From
Guided Therapeutics, Inc.
Via
Business Wire
Guided Therapeutics Closes $3.3 Million Bridge Financing
September 07, 2022
From
Guided Therapeutics, Inc.
Via
Business Wire
Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan
July 20, 2022
From
Guided Therapeutics, Inc.
Via
Business Wire
Guided Therapeutics Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740
March 31, 2022
From
Guided Therapeutics, Inc.
Via
Business Wire
Guided Therapeutics Announces Start of Chinese Clinical Trial for Approval to Market and Sell LuViva in China
November 17, 2021
From
Guided Therapeutics, Inc.
Via
Business Wire
Guided Therapeutics Ships LuViva Devices to China for Start of Clinical Trial; Receives Additional $100,000 Payment
October 05, 2021
From
Guided Therapeutics, Inc.
Via
Business Wire
Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China
August 19, 2021
From
Guided Therapeutics, Inc.
Via
Business Wire
New European Published Study Shows LuViva Detects 20% More Precancerous and Cancerous Cervical Disease than HPV Test
July 28, 2021
From
Guided Therapeutics, Inc.
Via
Business Wire
Guided Therapeutics Receives News from Chinese State Food and Drug Administration that LuViva Meets Product Technical Requirements
July 20, 2021
From
Guided Therapeutics, Inc.
Via
Business Wire
Guided Therapeutics Replaces Convertible Note Facility and Significantly Reduces Dilution
June 03, 2021
From
Guided Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.